<DOC>
	<DOCNO>NCT01087190</DOCNO>
	<brief_summary>It recommend transplant recipient undergo tuberculin skin test ( TST ) transplantation . However , ability TST diagnose latent tuberculosis infection ( LTBI ) transplant candidate report suboptimal high rate false-negative false-positive result . The enzyme-linked immunospot assay ( ELISPOT ) detect interferon-gamma secrete T-cells diagnose tuberculosis infection give promising result immunocompromised patient well immunocompetent patient . The investigator perform randomize , open-label , prospective trial isoniazid ( INH ) prophylaxis base ELISPOT assay LTBI renal transplant recipient .</brief_summary>
	<brief_title>Isoniazid ( INH ) Treatment Based ELISPOT Assay</brief_title>
	<detailed_description>Our previous data show ELISPOT assay sensitive detect LTBI renal transplant recipient TST ( Kim SH , et al . Transplant Infect Dis 2010 Jan 25 [ Epub ahead print ] ) . However , study eagerly await determine efficacy isoniazid ( INH ) prophylaxis base ELISPOT assay LTBI renal transplant recipient . All adult patient admit renal transplantation May 2010 April 2013 Asan Medical Center , Seoul , South Korea , prospectively enrol . INH ( 300 mg/day 9 month ) prophylaxis group prophylaxis group ( control group ) randomly assign patient baseline positive ELISPOT assay regardless result TST . The investigator compare cumulative probability develop active TB transplantation INH prophylaxis group control group primary outcome . Secondary outcome adverse drug reaction , rejection episode , graft survival , mortality .</detailed_description>
	<mesh_term>Isoniazid</mesh_term>
	<criteria>16 year Kidney transplant recipient Patients receive isoniazid treatment due abnormal liver function ( i.e . ChildPugh Score B C ) Patients clinical risk factor latent tuberculosis infection 1 . Close contact person pulmonary TB within past year 2 . Abnormal chest radiography prior prophylaxis 3 . A history untreated inadequately treat TB 4 . New infection ( i.e . recent conversion TST positive status ) If kidney transplant donor clinical risk factor latent tuberculosis infection , transplant recipient donor exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>kidney</keyword>
	<keyword>transplantation</keyword>
	<keyword>tuberculosis</keyword>
	<keyword>ELISPOT</keyword>
	<keyword>isoniazid</keyword>
</DOC>